Doc, I can't help it either but I am having a sane moment. The more we devote WHOLE threads to this clown, instead of opko, the Bryaner we get, Bryaner, see that, now I am creating Bryan VOCAB, I guess my sane moment was just that, a moment.
I do not even want to look in the mirror, afraid I might see a little shade of Bryan.
Not right, when Bryan gloats on down days I just shake my head, but if we ALL LOOK in the mirror there is a little Bryan in all of us if we gloat on up days, just sayn.
Yes, but it would not let me copy and paste, fat, bald, and UUUGLY.
A web page about our own jerk, your kidding, excerpt as proof:
Who ARE these people?
Online comment forums create ample opportunity for behavior of such extreme jerkitude that it can drive even the most patient Netizens batty. You know what I'm talking about: The know-it-alls, fight-starters, and doctrinaire zealots who seem to frequent every message board on the entire 'Interwebs', using any and every topic as a springboard for their sociopathic gratification. We've sifted through pages of forum messages to find the most absolutely asinine tactics. So get ready to cringe: On the pages that follow you'll meet our nominees for the 12 biggest jerks of the Web's online forums.
For additional coverage of the jerky and embarrassing demimonde of the Web, check out these stories:
The Russell announced on the 20th additions, deletions, so many stocks in those indexes have bounced around since then opko included. 9.20 down to 8.52 back up to about 9.10 today. All in a week. I think opko might trend higher now, we will see. The news from Opko keeps getting better, with three more items due this summer, Insurance news from England 50/50, Rolapitant NDA any day, Rayaldy top line in a couple months. So trending up over the summer has 3 catalysts.
Read the article, appears a thorough review of the prior phase1 phase 2 L-brain study. Curious why it took years for this review. Unless the phase 3 study made them go look at prior research. AF can no longer use the no peer review argument.
The Lakewood piece is a great reference to see the development of opko, the companies and technologies bought, and the companies evolution. That part is factual. He takes great pains to show opko's failed optics program, but leaves out the part where Frost SOLD the bulk of it at a profit to an English company. He mentions the aqushunt, and pink eye med as MIA, well opko still does own those patents, Opko now also owns qusome tecnology that could be paired with the pink eye med. Those items are in our Mexican research facility, but are low priority.
If Frost only paid 2M for Rolapitant it must be garbage he argues, but he fails to mention the 27 million or so in royalties beyond the initial price opko owes. This drug goes to FDA this summer, Opko made a huge initial profit here too. The Ceo at TSRO once developed the number one chemo nausea drug, Lakewood ignores this fact. So when TSRO approached OPKO for the drug it made a ton of sense.
Lakewood gave a great timeline and how Opko evolved but he failed miserably at understanding the current pipeline. His let them take OTC vit D and claim that calcitriol competes with Rayaldy are out right falsehoods, and designed to hammer his thesis home, he either knew better or received poor research.
4k launched on two continents, Rolapitant going to fda, clarifications on calcitriol vs Rayaldy, HGH progressing etc., one by one his thesis is crumbling and turning into trash and being exposed for what it was, manipulation.
Why should July be different than June? Unless there is news there is no catalyst. Until top line data from a phase three, maybe a new partner deal, or a buy out I see nothing moving arry? In fact the chart is at the inflection point, could head back to 4.50, where it recently failed or 4.00 Asco did not get it to 5.00, the Wells conference did not get it to 5.00, The Biogen, collaboration moved it .15, to move it to 4.25, umm, initiating a slow run to 4.48 which stalled, we are back at 4.23, So WHY JULY??
Until there is news I SEE nothing moving this up, but more drifting around current levels, 4-4.45
Tough call, either smartest ( luckiest ) guy if it pans out, or stupidest, ( unluckiest ) if the phase studies fail to meet the given P value. Well the guy with the house credit line is in this race too. But 57 posts, OMG, and I post a lot, that is a week or two for me.
go to the movies, have a beer, NWBO will still be here when you get back, I PROMISE. One man cheering section, sitting in the FRONT row.. the wind up, the pitch, and AF is out, LP wins, TURTLE collapses with joy, the paramedics rush to side, make him drink a gallon of beer, he survives a close one.
LOL, maybe, but my approach is to wipe out his argument with the truth. Read both, I am biased I guess, but my stand on Rayaldy is backed up in med literature. His argument is FROM/or similar to the Lakewood hit piece, whatever. I figure this too, by putting out the real facts others who do not understand Rayaldy get a better insight. When they first bought this technology/drug I thought #$%$ vitamin D, um why not rite aid, they have it so what is the catch??? So it is a normal first reaction.
The two soon to be Generic drugs are not a competing drug to Rayaldy. From an excerpt from the Seeking Alpha article Dr. Cannell, founder of Vitamin D council wrote:
Rayaldy should not compete with calcitriol or calcitriol-like drugs. When people lose their kidney function, they lose the ability to make their own calcitriol so calcitriol or calcitriol like drugs have to be administered. Also, calcitriol does not treat vitamin D deficiency but Rayaldy does. People with advanced kidney disease will need to take both calcitriol and Rayaldy but studies suggest Rayaldy will lower the dose of calcitriol they need, so in that sense they will compete indirectly.
4k score detects 95% of all aggressive prostate cancers, and misses about 5%, biopsies miss in that 5% neighborhood also. So basically a biopsy is not any better at detecting cancer than 4k. You make a valid point regarding the national Health Ins. in England. There are several groups petitioning for it in England, and with the completed phase 3 it is a matter of time, months, not years.
Strange, and not finding fault, but you made the same ERROR lakewood did. He also thought calcitriol and a Vitamin D drug would compete, so why buy Vitamin D. The OTC argument was also a Lakewood fallacy. OTC degrades in under an hour and because of the poor kidney function little/no D is absorbed. Calcitriol in the ABSENCE of a steady supply of D ( Rayaldy ) causes calcium, arteries, heart, and bone issues. As Dr Cannel points out patients need both, but they will NEED a smaller dose of generic calcitriol. There is also the chance that with a treatment like Rayaldy, more Drs. will also prescribe calcitriol because Rayaldy will help ELIMINATE the NEGATIVE side affects of Calcitriol.
Since you sold, good luck, but hope this clears up some of your misconceptions behind the two lead products. If you decide to buy back again you just might have a clearer steadier conviction about the pipeline.
Where R U seeing, not that it matters, where Credit Suisse sold out? At Nasd markets I see GS sold 10k shares, and CS sold 45%, but I ALSO SEE GEORGE SOROS bought in TOO, and net additions about 1m shares. I see 17 new positions only 2 sold out, blackrock sold out in one fund but added in three others, and whitebox sold out, combined 604K shares. I think the bigger news is Soros took a tiny 100K position than others making fund adjustments. The bottom line is up 17 new holders including Soros not that SOROS making a 750k invest is big, under .00001 of his holdings, but curious.
There is a small dowside gap at 5.73 and an upside gap at 8.50,both are on the table, I will not bet either way.
Opko, with 4 owned phase 3, plus one partnered phase 3. The pipeline appears boring, no exciting cancer drugs, etc.. Their pipeline does address some unmet, under researched items though. Vitamin D for kidney patients because they can not absorb and utilize OTC vitamin D. Human Growth Hormone currently DAILY injections, opko's drug is once a week. They state 2 divisions, biologic and diagnostic, but there is from my take 3 divisions, classic pharma, selling generics, veterinary, vitamins, etc. Just launched first diagnostic test, the CEO buys shares on a regular basis. OH, and heavily shorted. A late 2016 timeline should see revenue over 1b, addressable market is over 20B, so 1B is conservative. I see it getting to 28-32 in about 2 years from current 8-9. Current revenue 100M, cash 156M, enough cash for 1 year minimum. Battleground stock for sure, if you never heard of it, Research Dr. Phil Frost, founder Ceo, also Ceo of Teva but leaving that post later this year.
Opko is in at least one of these indexes, this might account for part of recent volatility.
Surprised LTS, PT ( 14.50 ) and Oppenheimer ( 12 )or Barrington ( 11 )did not chime in. HGH protected to 2028, orphan drug with EXCELLENT phase 2.
price target 11, consensus PT 12.33 according to Analyst rating network. Jefferies reiterates buy after release of phase 2 data on hgh.